Please login to the form below

Not currently logged in
Email:
Password:

Amgen announces 380 US job cuts

Amgen is to cut 380 R&D jobs in the US as the biotechnology company aims to streamline its operations

Amgen is to cut 380 R&D jobs in the US as the biotechnology company aims to streamline its operations.

Mary Klem, director of media relations at the company, said the job losses were "targeted and strategic", with no particular therapy area affected or sites to be shut down.

Jobs will go at research facilities in Thousand Oaks and San Francisco in California, as well as in Seattle and Massachusetts. Cuts are also expected in the UK.

Klem said: "We have lots of molecules moving into later stages of development, which means more expensive stages of development."

Amgen also announced former Bristol-Myers Squibb (BMS) senior vice president, commercial operations, Tony Hooper as the company's executive vice president, global commercial operations, effective October 26.

Hooper spent 16 years at BMS where his roles included running the BMS commercial business in North America, Asia, Middle East, Africa, South America and Europe.

He said: "It's a privilege to join Amgen, a company well-known for scientific innovation and developing life-changing therapies for people with serious illnesses."

20th October 2011

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Origins Insights

Origins are part of the Resonant Group. Using novel research methodologies, we dig deeper to deliver authentic audience experiences that...

Latest intelligence

When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...